Our deeply curated real world data accelerates drug development informing the decisions and actions that will deliver the best drugs to patients faster and at a lower cost.
“COTA was founded in 2011 by oncologists, engineers, and data scientists, with one aim in mind: to transform cancer care so that every patient gets the right treatment. That’s not a mission we can achieve alone. We are committed to working with providers, payers, life sciences companies, patients and the FDA to change how cancer is studied and treated.”
Andrew Pecora, M.D. Founder & Chairman
The Role of Real World Data in Bringing Medication to Market and Beyond with Bruno Villetelle
In this episode of Real World Talk, host Emily Di Capua talks to Bruno Villetelle, Head of Data and Digital for Novartis. They discuss the ways real world data is being used to innovate drug development and delivery so that patients can benefit from new discoveries sooner.
The Lancet Rheumatology Publishes Additional Findings on Tocilizumab, Fueled by Real-World Data
A recent observational study using real world data shows promising results from using tocilizumab in patients with severe COVID-19. According to study co-author Shivam Mathura, “While these results need to be further validated through clinical trials, we are thrilled to provide early insights to those in the field as we continue to fight this pandemic.”
2020 MedTech Breakthrough Awards Recognize COTA as the Best Overall Medical Data Solution Provider
COTA, Inc. is pleased to announce that MedTech Breakthrough has named COTA as a winner in the fourth annual MedTech Breakthrough Awards program for the “Best Overall Medical Data Solution Provider” award.